Department of Surgery and Critical Care Medicine and Keenan Research Centre of Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Surg Infect (Larchmt). 2010 Jun;11(3):275-81. doi: 10.1089/sur.2010.024.
The Surviving Sepsis Campaign (SSC) was launched in 2002 as a collaborative initiative of the European Society of Intensive Care Medicine (ESICM), the International Sepsis Forum (ISF), and the Society of Critical Care Medicine (SCCM). Its objective was, through the development and promulgation of evidence-based guidelines that facilitated the application of knowledge derived from clinical trials to bedside practice, to effect a 25% reduction in the relative risk of death from severe sepsis and septic shock.
The evolution and content of the SSC is summarized and the scientific basis of the conclusions is reviewed from the literature.
The SSC developed evidence-based management guidelines and undertook a broad educational program to implement them by integrating their recommendations into resuscitation and management bundles. The process engaged practitioners in North America, Europe, and South America and was supported by professional societies around the world. It also engendered controversy based on accusations of undue industry influence and some dissatisfaction among individuals who were antagonistic toward protocolization of care. By its conclusion, more than 22,000 patients with sepsis had been entered in the SSC database, and analysis of the results showed that participation in the SSC was associated with a 5.4% absolute survival benefit.
The SSC has impacted the care of septic patients and catalyzed changes that are likely to persist and evolve.
拯救脓毒症运动(SSC)于 2002 年作为欧洲重症监护医学学会(ESICM)、国际脓毒症论坛(ISF)和重症监护医学学会(SCCM)的合作倡议发起。其目标是通过制定和颁布基于证据的指南,促进将临床试验中获得的知识应用于床边实践,从而使严重脓毒症和脓毒性休克患者的死亡相对风险降低 25%。
总结了 SSC 的发展和内容,并从文献中回顾了结论的科学依据。
SSC 制定了基于证据的管理指南,并通过将其建议纳入复苏和管理捆绑包来实施广泛的教育计划。这一过程吸引了来自北美、欧洲和南美洲的从业者,并得到了世界各地专业协会的支持。它还引发了争议,有人指责其受到了不当的行业影响,也有人对护理规范化持反对态度。到项目结束时,已有超过 22000 名脓毒症患者被纳入 SSC 数据库,对结果的分析表明,参与 SSC 与 5.4%的绝对生存获益相关。
SSC 已经影响了脓毒症患者的治疗,并促使发生了可能持续和演变的变化。